|
|
|
|
|
| Zarate-Segura, P.; Bastida-Gonzalez, F.; Ellison, J.; Gallardo-Romero, N.; Loparev, V.; Velasco-Villa, A.. |
| Rabies is one of the oldest and most devastating diseases, typically a 100% case mortality rate. Antemortem rabies diagnosis in humans is important to institute infection control procedures and avoid further exposures of health personnel and other people who may have been in contact with saliva of the patient, to determine epidemiologically if other individuals were exposed to the same source, to monitor disease progression during experimental therapeutic interventions, to prevent cross infection during organ transplantation, and if negative, to examine other differential diagnoses. Four samples are recommended for antemortem testing of rabies in humans (saliva, serum, nuchal skin biopsy and cerebrospinal fluid) in which antibodies, viral antigens and... |
| Tipo: Info:eu-repo/semantics/article |
|
| Ano: 2013 |
URL: http://www.revistamvez-crmvsp.com.br/index.php/recmvz/article/view/230 |
| |
|
|
| Kuzmina, N.; Ellison, J.; Orciari, L.; Marissen, W.; Kuzmin, I.; Rupprecht, C.. |
| The demand for rabies immune globulin (RIG) for post-exposure prophylaxis (PEP) is significant. Unfortunately, the cost of RIG is prohibitive for many patients in developing countries. Several monoclonal antibodies (MAbs) which neutralize rabies virus (RABV) have been proposed as a replacement for conventional RIG due to the ability of their large-scale production at a reduced cost. In the present study, we generated 487 RABV glycoprotein (G) sequences from a variety of viral lineages, and supplemented the dataset with 154 complete and 115 partial G sequences available in GenBank. The objective was to evaluate variability of known MAb-binding epitopes on the G, which may preclude virus neutralization. The analysis demonstrated that binding site of MAb CR57... |
| Tipo: Info:eu-repo/semantics/article |
|
| Ano: 2013 |
URL: http://www.revistamvez-crmvsp.com.br/index.php/recmvz/article/view/247 |
| |
|
|
| Marissen, W. E.; Niezgoda, M.; Ellison, J.; Franka, R.; Kuzmina, N.; Kusmin, I.; Taylor, T.; Rupprecht, C.. |
| The currently recommended prophylaxis for individuals exposed to rabies virus is the combined administration of rabies vaccine and rabies immune globulin (RIG). However, limited supply hampers the availability of RIG, particularly in enzootic areas. To circumvent the global RIG limitation we aimed to develop a human monoclonal antibody combination, CL184, for rabies post-exposure prophylaxis (PEP) that would replace the plasma origin RIG. CL184 consists of two human IgG1 mAbs, CR57 and CR4098, which are directed against non-overlapping rabies virus (RV) glycoprotein epitopes. Previously, we have shown that the in vitro breadth of neutralization of CL184 against a large panel of street RV of various animal origins as well as in vivo protection by CL184 in a... |
| Tipo: Info:eu-repo/semantics/article |
|
| Ano: 2013 |
URL: http://www.revistamvez-crmvsp.com.br/index.php/recmvz/article/view/249 |
| |
|
|
|
